{
  "docId": "019de073-8606-762c-9e2e-06d280bc8199",
  "docSlug": "fe3546a131d6b03dbc05b580d2cda1c4",
  "documentTitle": "CTI BioPharma | Investor Presentation Deck | 24 slides",
  "authorId": "cti-biopharma",
  "authorName": "CTI BioPharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 17,
  "pageCount": 24,
  "prevPage": 16,
  "nextPage": 18,
  "slideType": "peer_benchmark",
  "function": "compare_peers",
  "density": "overcrowded",
  "nDataPoints": 6,
  "notes": "The slide compares two different clinical trial datasets (PERSIST-2 vs MOMENTUM) to highlight efficacy.",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de073-8606-762c-9e2e-06d280bc8199/17",
  "deckHref": "/decks/019de073-8606-762c-9e2e-06d280bc8199",
  "deckJsonHref": "/decks/019de073-8606-762c-9e2e-06d280bc8199.json",
  "deckAnchorHref": "/decks/019de073-8606-762c-9e2e-06d280bc8199#slide-17",
  "components": [
    {
      "bbox": {
        "h": 0.5,
        "w": 0.4,
        "x": 0.55,
        "y": 0.15
      },
      "kind": "chart",
      "text": "Momelotinib (Momentum) Improvement in TI and transfusion rate among patients who required RBC transfusions at baseline",
      "attrs": null,
      "subkind": "bar-grouped",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "90fca943-dd76-4686-af77-04ee6530876c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.45,
        "x": 0.05,
        "y": 0.15
      },
      "kind": "chart",
      "text": "PACRITINIB (PERSIST-2) Transfusion Independence (TI) in non-Ti patients",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e062a678-adee-4a8f-889f-ca8fcd859916",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.4,
        "x": 0.55,
        "y": 0.75
      },
      "kind": "paragraph",
      "text": "TI defined as absence of transfusions in the terminal 12 weeks of the 24-week randomization period, and all hemoglobin levels during the 12-week interval of ≥8 g/dL.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2613bbef-038c-4af5-ba82-b9859eba7097",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.45,
        "x": 0.05,
        "y": 0.75
      },
      "kind": "paragraph",
      "text": "Patients with an available 24-week visit (evaluable) who were non-TI (any red blood cell [RBC] transfusions in 90 days prior to the first dose or a baseline hemoglobin <8 g/dL). TI was defined as no RBC transfusions and no hemoglobin level <8 g/dL over any 12-week period through week 24.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3556dbde-f8e3-4f13-aa1a-3876fe63efd4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.05,
        "y": 0.9
      },
      "kind": "source-note",
      "text": "Data shown for illustrative purposes only, no head-to-head comparative studies have been conducted. BAT=Best available therapy included ruxolitinib and hydrea. Oh S, et al. SOHO 2022; Abstract MPN-145, Mesa, R, et al. ASCO 2022; Mascarenhas J, et al. JAMA Oncol. 2018;4(5):652-659.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7f76b529-5c3e-48fa-8033-82254c17686e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.7,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Pacritinib Improves Transfusion Independence (TI)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3088b6f8-6829-4a2b-9843-5b13f02132ce",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Slide recipe: the peer-gap chart",
      "slug": "peer-gap-chart-recipe",
      "agent": "designer",
      "layer": "slide",
      "matchId": "40005318-7521-4f49-8cf1-c6f5631c16a2",
      "evidence": "chart/bar-grouped: Momelotinib (Momentum) Improvement in TI and transfusion rate among patients who required RBC transfusions at baseline",
      "confidence": 0.7
    }
  ],
  "frameworks": [
    {
      "name": "comparison_frame",
      "slug": null,
      "matchId": "55a86d1f-f940-4fcd-bc30-90dba162873d",
      "evidence": "Side-by-side presentation of clinical trial results for competitive positioning.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}